FDA Protects Neonatal Parenteral Nutrition Supply

The FDA issued an immediately effective guidance intended to help prevent a potential supply gap in neonatal starter parenteral nutrition, which provides intravenous nutrients to premature and critically ill newborns who cannot be fed by mouth or through a tube.

The agency acted after children’s hospitals raised concerns about continued access following the discontinuation of certain standardized neonatal starter products made by two outsourcing facilities that are permanently closing. Starter formulations may be needed soon after birth, making continuity particularly important for premature and critically ill newborns.

The guidance, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates, describes temporary regulatory and enforcement priorities for specified compounded products. It applies to certain state-licensed pharmacies, federal facilities, and outsourcing facilities operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

The FDA said the temporary framework is designed to support hospital access while longer-term solutions are developed. The announcement did not identify a confirmed shortage or provide a timetable for implementing a longer-term solution.

The agency will continue monitoring current and anticipated supply needs and assess whether additional measures are necessary as the situation develops.

Source: US Food and Drug Administration. FDA takes steps to maintain newborn access to life-saving starter nutrition products. Press announcement. US Food and Drug Administration; September 4, 2026. Accessed September 6, 2026.